October 15, 2021

The U.S. FDA has approved a new indication for Genentech’s Tecentriq® (atezolizumab) for use as an adjuvant treatment following surgery and platinum-based chemotherapy in adults who have Stage II-IIIA non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 ≥ 1%, as determined by an FDA-approved test.

  • Tecentriq is now the first FDA-approved cancer immunotherapy indicated for adjuvant treatment of NSCLC. In cancer, adjuvant therapies are typically used following primary therapies such as surgery for tumor removal to reduce the risk of disease
  • First FDA approved in 2016, Tecentriq has multiple indications to treat NSCLC, and is also indicated to treat urothelial carcinoma, small cell lung cancer, hepatocellular carcinoma, and
  • Recommended dosing for adjuvant treatment of NSCLC is 840mg every two weeks, 1,200mg every three weeks, or 1,680 mg every four Treatment should continue for up to one year or until disease recurrence or unacceptable toxicity occur.
  • Tecentriq is administered via intravenous infusion over the course of 60 minutes for the first infusion and, if the first infusion is tolerated, 30 minutes for subsequent infusions.
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More